Advanced in Stomach Cancer

Dr. Ronan J. Kelly

Internal Medicine | Oncology
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
28 Years of Experience
Advanced in Stomach Cancer
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronan Kelly is an Internal Medicine specialist and an Oncologist in Dallas, Texas. Dr. Kelly has been practicing medicine for over 28 years and is rated as an Advanced provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreaticoduodenectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles and participated in 5 clinical trials in the study of Stomach Cancer.

Graduate Institution
National University Of Ireland, 1998.0
Residency
Internal Medicine, Beaumont Hospital
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine
Fellowships
Medical Oncology, Waterford Regional HospitalWaterford Ireland
Medical Oncology, Beaumont Hospital
Medical Oncology, The Royal Adelaide Hospital
Medical Oncology, National Cancer Institute, NIH
Oncology, National Cancer Institute, NIH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246
Call: 972-449-0540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit/Resistance to Cancer Therapeutics.
The Texas Immuno-Oncology Biorepository: Collection of Patients' Biospecimens for Analysis of Immunological and Molecular Biomarkers That Predict Benefit/Resistance to Cancer Therapeutics.
Enrollment Status: Recruiting
Publish Date: October 06, 2025
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Biological
Study Drug: Margetuximab+Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Relatlimab, Carboplatin, Paclitaxel
Study Phase: Phase 1
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

107 Total Publications

NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.
NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.
Journal: Frontiers in immunology
Published: May 22, 2025
View All 107 Publications
Similar Doctors
Distinguished in Stomach Cancer
Dr. Aravind R. Sanjeevaiah
Oncology | Hematology
Distinguished in Stomach Cancer
Dr. Aravind R. Sanjeevaiah
Oncology | Hematology

Baylor Scott & White Oncology Waxahachie

Waxahachie, TX 
 (28.7 miles away)
469-800-9500
Experience:
23+ years
Languages Spoken:
English
See accepted insurances

Aravind Sanjeevaiah is a Hematologist and an Oncologist in Waxahachie, Texas. Dr. Sanjeevaiah has been practicing medicine for over 23 years and is rated as a Distinguished provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Colorectal Cancer, Stomach Cancer, Neuroendocrine Tumor, and Gastrointestinal Stromal Tumor.

Advanced in Stomach Cancer
Dr. Andrew S. Paulson
Oncology | Internal Medicine
Advanced in Stomach Cancer
Dr. Andrew S. Paulson
Oncology | Internal Medicine

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (0.1 miles away)
972-449-0540
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Paulson is an Oncologist and an Internal Medicine provider in Dallas, Texas. Dr. Paulson has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Gastrostomy, and Endoscopy.

Advanced in Stomach Cancer
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology
Advanced in Stomach Cancer
Dr. Meera S. Shreedhara-Vasudha
Oncology | Hematology Oncology

Texas Oncology PA

4215 Joe Ramsey Blvd, 
Greenville, TX 
 (44.5 miles away)
903-408-5112
Languages Spoken:
English, French, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Meera Shreedhara-Vasudha is an Oncologist and a Hematologist Oncology provider in Greenville, Texas. Dr. Shreedhara-Vasudha is rated as a Distinguished provider by MediFind in the treatment of Stomach Cancer. Her top areas of expertise are Leukocytosis, Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, and Paget Disease of the Breast. Dr. Shreedhara-Vasudha is currently accepting new patients.

VIEW MORE STOMACH CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kelly's expertise for a condition
ConditionClose
    • Distinguished
    • Esophageal Cancer
      Dr. Kelly is
      Distinguished
      . Learn about Esophageal Cancer.
      See more Esophageal Cancer experts
    • Gastroesophageal Junction Cancer
      Dr. Kelly is
      Distinguished
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Advanced
    • EGFR Positive Lung Cancer
      Dr. Kelly is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Lung Adenocarcinoma
      Dr. Kelly is
      Advanced
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Lung Cancer
      Dr. Kelly is
      Advanced
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Kelly is
      Advanced
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    • Small Cell Lung Cancer (SCLC)
      Dr. Kelly is
      Advanced
      . Learn about Small Cell Lung Cancer (SCLC).
      See more Small Cell Lung Cancer (SCLC) experts
    • Stomach Cancer
      Dr. Kelly is
      Advanced
      . Learn about Stomach Cancer.
      See more Stomach Cancer experts
    View All 7 Advanced Conditions
    • Experienced
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Kelly is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Anal Cancer
      Dr. Kelly is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Balloon Sinuplasty
      Dr. Kelly is
      Experienced
      . Learn about Balloon Sinuplasty.
      See more Balloon Sinuplasty experts
    • Endoscopy
      Dr. Kelly is
      Experienced
      . Learn about Endoscopy.
      See more Endoscopy experts
    • Inappropriate Sinus Tachycardia (IST)
      Dr. Kelly is
      Experienced
      . Learn about Inappropriate Sinus Tachycardia (IST).
      See more Inappropriate Sinus Tachycardia (IST) experts
    • Large-Cell Lung Carcinoma
      Dr. Kelly is
      Experienced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.